Key result
An 88-year-old woman treated with rivaroxaban for atrial fibrillation developed a severe spontaneous hemopericardium in the absence of other interacting drugs.
Case Report (n=1)
No
This case highlights the rare but severe risk of spontaneous hemopericardium in patients treated with rivaroxaban, even in the absence of interacting drugs.
Warrants vigilance for hemopericardium in elderly AF patients on rivaroxaban; single case leaves open true incidence and risk factors.
We describe a case of an 88-year-old woman with a severe bluntly ematic pericardial effusion. Radiological and laboratory examinations excluded all the most common causes of hemopericardium, and the diagnosis of spontaneous hemopericardium associated with the treatment with rivaroxaban was made. This is the first case report describing a hemopericardium in a patient treated with rivaroxaban who did not take other herbal products or drugs that may significantly increase rivaroxaban blood levels. This report emphasizes the need for the careful use of new oral anticoagulants, and the importance of taking in mind uncommon side effects. Spontaneous hemopericardium should be considered in these patients.
No takes yet. Share an insight, caveat, or question.
Longobardo et al. (2019) conducted a case report in Spontaneous hemopericardium (n=1). Rivaroxaban was evaluated on Spontaneous hemopericardium. An 88-year-old woman treated with rivaroxaban for atrial fibrillation developed a severe spontaneous hemopericardium in the absence of other interacting drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: